Diabetic Retinopathy Market Growth, Price and Forecasts To 2025 Diabetic Retinopathy Market - Global Industry Anal

Diabetic Retinopathy Market - Global Industry Analysis, Size,
Share, Growth, Trends, and Forecast 2017 – 2025
Diabetes is a lifelong chronic disease caused by excessive levels of glucose in the blood mainly
due to lack or insufficiency of insulin hormone to metabolize the glucose in the blood. This accumulated
glucose level in the blood does not reach body cells and severely affects multiple organs such as
kidneys, eyes, nerves, blood vessels, and heart. Diabetic Retinopathy is one of the common diabetic
eye diseases characterized by the damaged blood vessels in the retina. The damaged blood vessels
and nerves lead to blurring of vision, vision impairment, and eye hemorrhage. If left untreated, it may
lead to retinal detachment and blindness. Non Proliferative Diabetic Retinopathy (NDPR) and
Proliferative Diabetic Retinopathy (PDR) are the two stages of diabetic retinopathy. Diabetic
retinopathy can be treated through medicines, laser surgery, and vitrectomy. Diabetic retinopathy can
develop in any individual suffering from type 1 or type 2 diabetes. This disease is the leading cause of
blindness in the U.S.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22910
Increase in prevalence of diabetes across the globe is anticipated to drive the diabetic retinopathy
market. According to National Center for Biotechnology Information, 126 million people were affected
by diabetic retinopathy in 2010; more than 191 people are likely to be affected by Diabetic retinopathy
by 2030. According to the American National Health and Nutrition Examination Survey conducted
between 2005 and 2008, 28.5% of diabetic patients had some degree of DR, while 4.4% of patients
suffered from vision threatening diabetic retinopathy. Increase in geriatric population, high prevalence
of obesity, and rise in sedentary lifestyle are the key factors driving the global diabetic retinopathy
market. Furthermore, increase in awareness about the early detection of Diabetic retinopathy among
diabetic patients across the globe, rise in healthcare facilities in emerging and developed countries,
and availability of multiple treatment options with advanced technology are the factors propelling the
market. However, negligence of Diabetic retinopathy, poor planning of Diabetic retinopathy treatment
in low income countries, and lack of skilled professionals for treatment of Diabetic retinopathy in
emerging and less developed countries are the key restraining factors of the market.
The global diabetic retinopathy market can be segmented based on stages of diabetic retinopathy,
type of treatment, end-user, and region. There are primarily two stages of diabetic retinopathy: Non
proliferative diabetic retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR). NPDR is early
stage of Diabetic retinopathy characterized by the leakage of blood vessels, resulting in deposition of
blood and blood components in retina. PDR is the advanced stage of Diabetic retinopathy
characterized by abnormal growth of blood vessel, which results in swelling of retina called Diabetic
Macular Edema (DME). Diabtetic retinopathy can be treated and controlled through injections of
Vascular Endothelial Growth Factor (VEGF), laser treatments, and vitrectomy. Laser treatment is
further classified into focal laser treatment and scattered laser treatment.
In terms of geography, the global diabetic retinopathy market can be divided into North America,
Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate